Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cholesterol Drugs Costsharing topic
No spam. Unsubscribe anytime.
Committee approves substitute to remove co‑pay for rosuvastatin and related LDL drugs
Summary
Senate Health and Public Affairs advanced a committee substitute for SB443 unanimously (9–0) to eliminate cost sharing for rosuvastatin and related second‑line LDL‑lowering drugs for covered plans; OSI staff worked with the sponsor to refine language.
The Senate Health and Public Affairs Committee issued a unanimous do‑pass recommendation (9–0) on a committee substitute for SB443, which would eliminate cost sharing for rosuvastatin (a commonly prescribed statin), ezetimibe (a cholesterol absorption blocker), and narrow the prior‑authorization barriers to second‑line injectable LDL‑lowering therapies when clinically indicated.
Sponsor testimony noted that diagnosis is only half the outcome and that removing co‑pays would reduce barriers to treatment. The sponsor said the change primarily affects fully insured commercial plans and that the Office of Superintendent of Insurance (OSI) worked with bill staff to produce amendments that address high‑deductible plan interactions and other technical issues. Vyara Nakeva of OSI testified that the office had worked with the sponsor on improved language and urged passage of the revised bill.
Committee discussion was brief. Senators asked practical questions about plan networks and federal plans (TRICARE, Medicare), and OSI staff said the bill applies to commercial, fully insured plans and does not control federal programs.
The committee recorded a 9–0 vote for a do‑pass recommendation and sent the committee substitute forward; the sponsor said they would continue to work with OSI on implementation language before subsequent committee referrals.
Votes at a glance: SB443 (committee substitute) — Do pass recommendation, committee vote 9–0.
